AMP Health Review
Appears to have shut downAMP Health is closed and is not taking new patients. It charged from $199 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
AMP Health is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $199/mo. No longer offered.
See our top-rated GLP-1 providers →AMP Health sold compounded semaglutide and tirzepatide by telehealth. Its site has shown only a maintenance page since May 2026, and every product page redirects to it. Checked in October 2026.
Vetted alternatives to AMP Health
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
RxSpan MD
Best for: knowing which pharmacy fills the vial: it names Belmar Pharmacy
Editorial score · methodology
AMP Health at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $199/mo (Plus $79/mo subscription)
- FDA status
- 1 FDA warning letter (details below)
How AMP Health scores
AMP Health has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something AMP Health published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
5.0/10$199/month is exactly the median for compounded semaglutide across the sellers we compare.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
3.5/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on AMP Health
Last checked July 2026- Checked the listed price across 3 dose or plan tiers
- Checked FDA warning letters for AMP Health
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Cancelling AMP Health
Taken from the terms AMP Health publishes. Terms change, so check the current policy before you subscribe.
- Minimum commitment
- None
- Refund policy
- 30-day satisfaction guarantee
Medications AMP Health listed
AMP Health listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
Plus $79/mo subscription
Plus $79/mo subscription
Plus $79/mo subscription
In its favor
- Semaglutide cost $199 a month, exactly the $199 median for compounded semaglutide across the sellers we compare
- Tirzepatide cost $309 a month, close to the $269 median for compounded tirzepatide across the sellers we compare
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
Against it
- The FDA has issued AMP Health a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
AMP Health is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What AMP Health charged
AMP Health charged $199/month.
- Compounded semaglutide: $199/month
- Compounded semaglutide (oral): $199/month
- Compounded tirzepatide: $309/month
For compounded semaglutide, the median across the sellers we compare is $199/month, so AMP Health's $199 lands mid-market. Price is unlikely to be the deciding factor.
Bodybuilding Health+ dispenses semaglutide and tirzepatide from $179/month, which makes it the fair comparison to run before you commit here.
What AMP Health dispensed
AMP Health prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at AMP Health at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a proven equal to the shot.
Safety and disclosure
AMP Health told buyers its price before the medical questionnaire. The FDA has issued AMP Health a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
AMP Health is no longer taking new patients, so the choice is among the sellers that are still open. Belle Health is the nearest comparison we review, and worth reading alongside this. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
AMP Health is closed and is not taking new patients. It charged from $199 a month.
Where AMP Health is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider RxSpan MD.
If none of these fits, our guide to alternatives to AMP Health sets more sellers in the same category beside AMP Health on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
AMP Health has an FDA warning letter on record, dated February 20, 2026
This letter concerns false & misleading claims/misbranded. A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this AMP Health review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of July 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.